Twist Bioscience (TWST) Rating Lowered to Sell at Zacks Investment Research

Share on StockTwits

Twist Bioscience (NASDAQ:TWST) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

TWST has been the subject of several other reports. Cowen started coverage on Twist Bioscience in a report on Monday, November 26th. They set an “outperform” rating for the company. JPMorgan Chase & Co. started coverage on Twist Bioscience in a report on Monday, November 26th. They set a “neutral” rating and a $27.00 price objective for the company. Finally, Robert W. Baird started coverage on Twist Bioscience in a report on Monday, November 26th. They set an “outperform” rating for the company.

TWST stock opened at $21.06 on Tuesday. The company has a market capitalization of $590.06 million and a PE ratio of -0.83. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.72 and a quick ratio of 7.43. Twist Bioscience has a 12-month low of $12.38 and a 12-month high of $34.46.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, February 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.33). The firm had revenue of $11.49 million during the quarter, compared to the consensus estimate of $9.70 million. Analysts anticipate that Twist Bioscience will post -4.18 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC bought a new position in Twist Bioscience during the fourth quarter valued at $26,090,000. Apoletto Ltd bought a new position in Twist Bioscience during the fourth quarter valued at $10,503,000. BlackRock Inc. bought a new position in Twist Bioscience during the fourth quarter valued at $7,782,000. Intellectus Partners LLC bought a new position in Twist Bioscience during the fourth quarter valued at $4,076,000. Finally, Massachusetts Financial Services Co. MA bought a new position in Twist Bioscience during the fourth quarter valued at $5,068,000. 7.95% of the stock is owned by institutional investors and hedge funds.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Recommended Story: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply